BioSpace News Archive

Drug Development

Pliant Seeks $175 Raise on Heels of Promising Mid-Stage IPF Data

After reporting promising interim findings from the Phase IIa INTEGRIS-IPF trial, Pliant Therapeutics commenced a public stock offering of $175 million.

January 24, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Axcella Clears Regulatory Path for Long COVID Therapeutic (Updated)

Axcella Therapeutics’ Long COVID fatigue therapeutic is moving forward as the company received guidance from the MHRA and filed an IND with the FDA seeking a Phase IIb/III trial.

January 24, 2023
·
3 min read
·
Tristan Manalac
Drug Development

FDA Made the Right Call on Lilly’s Donanemab, Some Experts Say

Research hasn’t shown that removing amyloid plaques alone improves function in Alzheimer’s patients, said Sharon L. Rogers, CEO of AmyriAD.

January 24, 2023
·
4 min read
·
Lisa Munger
Drug Development

Study: Intranasal Delivery of Antibodies could Solve Delivery Problem for CNS Targets

Results from a study published in PNAS demonstrated that delivering therapeutics intranasally was sufficient to enhance functional recovery in rat models of ischemic stroke.

January 24, 2023
·
3 min read
·
Hayley Shasteen
How to Ask for More Responsibility at Work

There comes a time in every professional’s career when they need to ask for more responsibility at work. Read on to find out the right and wrong way to ask your manager to help you level-up in your role.

January 24, 2023
·
4 min read
·
Franklin Carpenter
Drug Development

Cassava’s Mixed Alzheimer’s Data Underwhelms Investors (Updated)

Cassava Sciences reported Phase II data from its Alzheimer’s candidate simufilam Tuesday. The company’s stock dropped 17% following the reveal.

January 24, 2023
·
3 min read
·
Heather McKenzie
Policy

Sen. Warren Leads Call for Prostate Cancer Drug Pricing Reform

A group of 25 senators, led by Sen. Elizabeth Warren (D-MA), is requesting that HHS Sec. Xavier Becerra exercise march-in rights for Xtandi (enzalutamide), a prostate cancer therapeutic.

January 24, 2023
·
5 min read
·
Gail Dutton
Hyloris Announces Commercial Partnership for Maxigesic® IV in 9 European Countries

Hyloris Pharmaceuticals SA announces that its partner AFT Pharmaceuticals has signed an exclusive licensing and distribution agreement with Salus Pharmaceuticals for Maxigesic® IV, a novel, dual mode-of-action non-opioid pain treatment delivered through intravenous infusion, in 9 European markets.

January 24, 2023
·
4 min read
Business

2023 Japan Prize Laureates Announced

The Japan Prize Foundation announced the winners of the 2023 Japan Prize on January 24, 2023.

January 24, 2023
·
2 min read
Basilea reports preliminary operating profit for 2022, significantly above guidance

Basilea Pharmaceutica Ltd announced that on an unaudited preliminary basis it expects to have achieved an operating profit of approximately CHF 18 million for the financial year 2022 and expects to report a net profit.

January 24, 2023
·
3 min read